Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc. is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery. Globus Medical also offers products for orthopedic trauma, including fixation systems and other devices used to treat fractures and support bone healing.

Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical serves customers in the United States and international markets through direct sales and distribution channels. In 2023, the company completed its combination with NuVasive, expanding its product offerings and global presence in spine and related musculoskeletal care. Dan Scavilla serves as the company’s chief executive officer, while founder David C. Paul serves as executive chairman.

Key Stats

• Today's Range: $77.05 to $77.76
• 50-Day Range: $73.36 to $88.48
• 52-Week Range: $58.32 to $101.40
• Volume: 145,346 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $10.45 billion
• P/E Ratio: 19.91
• Dividend Yield: N/A
• Price Target: $99.46
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 85% of companies evaluated by MarketBeat, and ranked 76th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Globus Medical has a consensus price target of $99.46, representing about 28.4% upside from its current price of $77.48.

Amount of Analyst Coverage

Globus Medical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.02%

Earnings Growth

Earnings for Globus Medical are expected to grow by 8.02% in the coming year, from $4.99 to $5.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 19.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 19.81, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 228.02.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 1.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.70% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 5.14.

Change versus previous month

Short interest in Globus Medical has recently increased by 24.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.78

News Sentiment

Globus Medical has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Globus Medical this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,413,400.00 in company stock.

Percentage Held by Insiders

18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 6,000
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Globus Medical: $99.46
• High Price Target: $123.00
• Low Price Target: $80.00
• Potential Upside/Downside: +28.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.91
• Trailing P/E Ratio: 19.81
• Forward P/E Ratio: 15.53
• P/E Growth: 1.23
• Net Income: $537.87 million
• Net Margins: 17.02%
• Pretax Margin: 20.99%
• Return on Equity: 14.57%
• Return on Assets: 12.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $3.14 billion
• Price / Sales: 3.31
• Cash Flow: $6.38 per share
• Price / Cash Flow: 12.15
• Book Value: $33.86 per share
• Price / Book: 2.29

Miscellaneous

• Outstanding Shares: 134,262,000
• Free Float: 109,585,000
• Market Cap: $10.40 billion
• Optionable: Optionable
• Beta: 0.96